SpringWorks Therapeutics (SWTX) Stock Price
SpringWorks Therapeutics Price
Revenue has compounded at 3.4% per year over the past 24 years to 191.59 M USD. Earnings per share have grown at 9.1% per year over the last 9 years. SpringWorks Therapeutics's net margin stands at -134.7%, down from -126.4% several years earlier. Analysts set a median price target of 47.94 USD, implying 2.0% above the current price. Of 11 analysts, 0 rate the stock a buy — an overall Hold consensus.
SpringWorks Therapeutics stock price
SpringWorks Therapeutics business model & stock analysis
Frequently asked questions about SpringWorks Therapeutics
The business model of SpringWorks Therapeutics Inc. is focused on developing and commercializing innovative targeted therapies for patients with severe rare diseases and cancer. The company aims to identify promising drug candidates and advance them through clinical development to address unmet medical needs. SpringWorks Therapeutics Inc. collaborates with both academic institutions and industry partners to leverage its expertise and optimize the development of potential treatments. By utilizing targeted therapies, the company aims to provide effective and personalized solutions for patients, with a focus on improving their overall quality of life.
SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.
Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.
SpringWorks Therapeutics Inc is primarily present in the United States.
SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.
Analysts currently set an average price target of 53.33 USD for the SpringWorks Therapeutics stock (median: 47.94 USD), implying +13.5 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the SpringWorks Therapeutics stock: 0 recommend buying, 8 holding and 3 selling. For 2026, analysts expect SpringWorks Therapeutics to generate revenue of 612.33 M USD and earnings per share of -0.84 USD.
Converted at the current exchange rate, the SpringWorks Therapeutics share trades at 41.93 EUR (46.99 USD).
The SpringWorks Therapeutics share (SWTX) is listed on 1 stock exchanges, including: NASDAQ (SWTX).
SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.
The expected revenue of SpringWorks Therapeutics is 612.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SpringWorks Therapeutics is -62.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SpringWorks Therapeutics is currently -56.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SpringWorks Therapeutics stock.
The price-to-sales ratio (P/S) of SpringWorks Therapeutics is currently 5.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SpringWorks Therapeutics stock.
The Eulerpool Quality Score for SpringWorks Therapeutics is 3/10.
The ISIN of SpringWorks Therapeutics is US85205L1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of SpringWorks Therapeutics is A2PRLN. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of SpringWorks Therapeutics is SWTX. The ticker symbol is used to trade SpringWorks Therapeutics shares on the stock exchange.
SpringWorks Therapeutics stock
SpringWorks Therapeutics Peer Group
SpringWorks Therapeutics Ticker
SpringWorks Therapeutics FIGI
All fundamentals and in-depth analysis of SpringWorks Therapeutics
Our stock analysis for SpringWorks Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SpringWorks Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.